Maryland Attorney General Brian Frosh announced Sunday Maryland will join more than 40 other states that are alleging the nation's largest generic drug manufacturers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs, including treatments for diabetes, cancer, arthritis and other medical conditions.
The lawsuit, filed in federal court in Connecticut on Friday, also names 15 individual senior executives responsible for sales, marketing and pricing.
In a statement, Frosh said the drugs named in the suit “are used by millions of people for conditions that range from diabetes to cancer to depression, and we allege that their scheme cheated vulnerable patients, the State of Maryland and health insurance programs to the tune of billions of dollars.”
According to the release, “the complaint lays out an interconnected web of industry executives where these competitors met with each other during industry dinners, ‘girls nights out,’ lunches, cocktail parties, golf outings, and communicated via frequent telephone calls, emails and text messages that sowed the seeds for their illegal agreements. Defendants used terms like ‘fair share,’ ‘playing nice in the sandbox,’ and, ‘responsible competitor’ to describe how they unlawfully discouraged competition, raised prices and enforced an ingrained culture of collusion.”
Connecticut Attorney General William Tong, a Democrat, said investigators obtained evidence implicating 20 firms.
"We have hard evidence that shows the generic drug industry perpetrated a multibillion dollar fraud on the American people," Tong said. "We have emails, text messages, telephone records and former company insiders that we believe will prove a multi-year conspiracy to fix prices and divide market share for huge numbers of generic drugs."
Tong said the investigation had uncovered a primary reason why the cost of health care — and specifically generic prescription drugs — has been so high in this country.
The surging prices of prescription drugs have drawn the attention of a number of politicians across the political spectrum from President Donald Trump to liberal Democratic presidential candidate Sen. Elizabeth Warren of Massachusetts.
The new court suit was the second that has been filed in the investigation. The first, filed in 2016, named 18 corporate defendants and two individual defendants. Two former drug company executives entered into settlement agreements and are cooperating with the attorneys general in the investigation.
A spokesman for one of the companies named in the suit, Teva Pharmaceuticals USA Inc., a wholly owned subsidiary of Israeli-based Teva Pharmaceuticals Industries Ltd, said Teva hasn't engaged in any conduct that would lead to civil or criminal liability.
"The allegations in this new complaint, and in the litigation more generally, are just that — allegations," Kelley Dougherty, a Teva vice president, said in a statement Saturday. "The company delivers high-quality medicines to patients around the world and is committed to complying with all applicable laws and regulations in doing so."
Investigators said the drugs covered in the suit account for billions of dollars of sales in the United States.
The suit was filed by 43 states and Puerto Rico with Connecticut taking the lead in the probe.
The suit alleges that for many years these makers of generic drugs had operated under an agreement not to compete with each other and to settle instead for what these companies referred to as a "fair share" of the market to avoid pushing prices down through competition.
But by 2012, the suit says that Teva and the other companies decided to "take this understanding to the next level." It alleges that "Teva and its co-conspirators embarked on one of the most egregious and damaging price-fixing conspiracies in the history of the United States."
The suit says that the companies sought not only to maintain their "fair share" of the generic drug market but also to "significantly raise prices on as many drugs as possible."
To accomplish this goal, the suit says that Teva selected a core group of competitors with which it already had "very profitable collusive relationships," and developed understandings to lead and follow each other's price increases.
The suit contends that this resulted in "many billions of dollars of harm to the national economy over a period of several years."
During a 19-month period beginning in July 2013, the suit says Teva significantly raised prices on approximately 112 different generic drugs and on at least 86 of those drugs colluded with a group it referred to as "high quality" competitors.
The suit says that the size of the price increases varied but was over 1,000% for a number of the drugs.
The suit says that the defendants knew their conduct was unlawful and usually chose to communicate in person or by cell phone "in an attempt to avoid creating a written record of their illegal conduct."
"When communications were reduced to writing or text messages, defendants often took overt and calculated steps to destroy evidence of those communications," according to the suit.
The civil suit is asking for a finding that the defendants' actions violated federal and state antitrust and consumer protection laws and is seeking a permanent injunction preventing the companies from continuing the conduct.
The suit also seeks reimbursement of profits from the actions and damages to be paid to the state agencies and consumers who were harmed by the drug company practices.